Anthropic hopes Powerful AI will “match or exceed the cognitive capabilities of top human experts across scientific disciplines”. Artificial intelligence (AI) specialist Anthropic has detailed its plans to dive deeper into the world of drug discovery and development as the…
Aspen Neuroscience is pursuing a $150 million IPO to fund Parkinson’s disease stem cell therapies. Click here to read an analysis of ASPE stock now. - Aspen Neuroscience is pursuing a $150 million IPO to fund Parkinson’s disease stem cell therapies. - ASPE’s lead…
OpenAI is trying to chip away at Anthropic’s lead with enterprises by fashioning itself as a cheaper, more flexible provider, Steph and I reported this weekend. But Anthropic's impressive prospectus for an initial public offering, filed Monday, shows OpenAI will…
Pursuant to the terms of the Agreement, Everkind will acquire 100% of the issued and outstanding Class A and Class B shares of Razroze for aggregate consideration of up to $250,000 CAD in common shares of Everkind ("Consideration Shares"): $125,000 CAD at closing…
Omabit has raised $2 million in seed financing led by Bright Ventures to advance an artificial intelligence platform designed to help life sciences companies analyze scientific evidence and make decisions throughout drug development. Omabit then uses the combined evidence to support…
This is not a story about 'AI creating a new drug all by itself.'The essence is that an AI company has moved from being a 'provider of drug discovery tools' to 'taking on research itself and participating in the…
Oct 26 (Reuters) - Drug developers Aspen Neuroscience and Bambusa Therapeutics launched their US initial public offering roadshows on Monday, adding to a wave of issuers from the biotech industry that have tapped the fall IPO window. The sector has been a…
Aspen Neuroscience, a Phase 1/2a biotech developing stem cell therapies for Parkinson’s disease, announced terms for its IPO on Monday.The San Diego, CA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17. Aspen Neuroscience,…
Lycia Therapeutics’ protein-degrading drugs are based on the research of Carolyn Bertozzi, a Stanford chemistry professor and Nobel laureate. Lycia’s lead drug candidate is in development for food allergy, where it could compete against the blockbuster Roche drug Xolair. Blocking…
Tracking the capital moving through Greater Philadelphia— funding rounds, M&A activity, and investment trends shaping Philadelphia, Southern New Jersey, and Delaware’s life sciences companies. A state-backed venture program has announced its latest round of investments, and most of the…
Biotech companies going public: IPO filings, pricing and debuts, and the state of the biotech IPO window.
An article joins this feed when it matches these terms. Each one is also a search of its own.